➡️ Allan highlighted their key partnership in North America, which ensures guaranteed revenue and collaboration with major cancer centers.


➡️ Additionally, he discussed the development of a finger-prick test for easier, mass screening, and plans to extend their reach to the UK and Europe, supported by non-dilutive funding to further advance and commercialize their technology.

By Mark Fairbairn
Recorded 20/6/2024

свернуть